Buprenorphine/naloxone (Suboxone®, Reckitt-Benckiser) is recommended for treating opiate addiction. Clinical guidelines do not specify the minimum duration of treatment required to achieve long-term remission. This study evaluated the impact of persistence on resource utilisation and healthcare charges.